Vol. 5 No. 3 (2025)
Reimbursement Reviews

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

decorative image of the issue cover

Published March 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses elexacaftor-tezacaftor-ivacaftor plus ivacaftor (Trikafta)
    • Aged 2 to 5 years
      • elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg (granules) plus ivacaftor 75 mg (granules)
      • elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg (granules) plus ivacaftor 59.5 mg (granules), oral
    • Aged 6 years and older
      • 50 mg elexacaftor, 25 mg tezacaftor, and 37.5 mg ivacaftor (combination tablet) plus 75 mg ivacaftor (tablet), oral
      • 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor (combination tablet) plus 150 mg ivacaftor (tablet), oral.
  • Indication: For the treatment of cystic fibrosis in patients aged 2 years and older who have at least 1 F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data.